United States: Off-Label Enforcement Developments (Vascular Solutions, Inc. Acquittal and Amarin Settlement)

Two important cases involving the permissible scope of speech regarding off-label marketing recently resolved in ways that should bolster efforts by drug and device manufacturers to secure their First Amendment rights to make truthful, non-misleading statements about potential off-label uses of their products. First, in a closely watched case in federal court in Texas, a jury acquitted a medical device manufacturer and its CEO of all charges, which included numerous off-label-related allegations. Second, the Food and Drug Administration ("FDA") settled a First Amendment lawsuit filed against it by a drug manufacturer, preserving a significant win that the manufacturer achieved earlier in the case.

Vascular Solutions, Inc. Acquittal

On February 26, 2016, a jury in the United States District Court for the Western District of Texas returned acquittals across the board in a case involving allegations that a medical device manufacturer engaged in off-label promotion. In United States v. Vascular Solutions, Inc., Cr. No. 14-926 (W.D. Tex.), a jury found Vascular Solutions, Inc. ("VSI"), and its chief executive officer, Howard Root, not guilty of all charges.

VSI manufactures the Vari-Lase device, a laser console that is used to treat varicose veins by ablation, meaning to dissipate them with intense heat. The FDA cleared the Vari-Lase device for treatment of superficial veins, but doctors sometimes used the device off-label to treat perforator veins, the short veins that connect the superficial and deep vein systems. VSI unsuccessfully sought FDA clearance for use of the Vari-Lase device to treat perforator veins and developed a special Vari-Lase "Short Kit" that, according to the government, was designed to make it easier to treat perforator veins.

The Department of Justice ("DOJ") charged VSI and Root in federal court in San Antonio with conspiracy to distribute misbranded and adulterated medical devices, and with distributing misbranded and adulterated medical devices, in violation of the Food, Drug, and Cosmetic Act ("FDCA"). DOJ alleged that VSI unlawfully distributed and promoted the Vari-Lase device, including the Short Kit, for a new intended (i.e., off-label) use to treat perforator veins; additionally, DOJ alleged that VSI misrepresented clinical data about the safety and effectiveness of the product for perforator vein ablation and misinformed doctors that Medicare and private payers would cover perforator vein procedures.

A significant portion of the pretrial briefing focused on how the First Amendment and its protection of truthful, non-misleading speech about off-label uses applied to DOJ's allegations against VSI and Root. At issue were the Second Circuit's landmark decision in United States v. Caronia, 703 F.3d 149 (2012), and a recent decision from the Southern District of New York, Amarin Pharma, Inc. v. FDA, 119 F. Supp. 3d 196 (2015). In Caronia, the Second Circuit reversed a pharmaceutical sales representative's conviction for conspiracy to introduce a misbranded drug into interstate commerce and held that "the government cannot prosecute pharmaceutical manufacturers and their representatives under the FDCA for speech promoting the lawful, off-label use of an FDA-approved drug." 703 F.3d at 169. Amarin extended Caronia, granting a drug manufacturer preliminary injunctive relief against the FDA and holding that all truthful and non-misleading speech about off-label uses is protected, including proactive, promotional statements made by a pharmaceutical manufacturer. 119 F. Supp. 3d at 226-28.

DOJ and the defendants sparred repeatedly about the impact of Caronia and Amarin on VSI. The district court ultimately charged the jury that if it found that "VSI's promotional speech to doctors was solely truthful and not misleading" it could not be the basis for a misbranding conviction.

On the second day of deliberations, the jury returned verdicts of not guilty on every count. VSI immediately issued a press release criticizing DOJ in harsh terms, calling for a review of "every current investigation of a medical device company concerning 'off-label' promotion." While the acquittals themselves have no precedential value, DOJ's loss, despite pursuing the prosecution in a supposedly favorable venue, raises serious questions about the continued viability of the government's off-label enforcement theories.

Amarin Settlement

Twelve days after the jury's verdict in VSI, on March 8, 2016, Amarin Pharmaceuticals, Inc. ("Amarin")—the plaintiff in the Amarin case on which the VSI defendants had based many of their First Amendment arguments—settled its lawsuit against FDA. The Amarin case had remained stayed since the district court issued its preliminary injunction opinion, which extended Caronia and endorsed many of Amarin's positions regarding the importance of protecting truthful, non-misleading speech about off-label use. A previous Ropes & Gray Alert, discussing the Amarin court's preliminary injunction ruling, is available here.

In the settlement, which the district court has already approved, FDA agreed to be bound by the district judge's rulings regarding the scope of permissible speech about Amarin's drug. See Stip. & Order of Settlement, Amarin Pharma, Inc. v. FDA, No.15 Civ 3588, ECF no. 84 (Mar. 8, 2016). Importantly, FDA recognizes "that Amarin may engage in truthful and non-misleading speech promoting [ ] off-label use" of its product and that "such speech may not form the basis of a prosecution for misbranding." Id. ¶ 1. The settlement also sets up a safe harbor process for the next four years by which Amarin and FDA may enter into a dialogue about "up to two proposed communications per calendar year" regarding off-label use and, should they disagree, seek the Court's intervention. Id. ¶ 5.

The biggest value in the Amarin settlement, however, is that it preserves the judge's preliminary injunction opinion. Until the parties settled, FDA had the option to attempt to limit or overturn the decision either in permanent injunction proceedings or on appeal. While the decision is not technically binding on any other courts, its persuasive value is likely to be significant, given the paucity of decisions in this area and the thorough, careful analysis in the opinion.


The jury's verdict in VSI and the Amarin settlement are the latest setbacks to the government's off-label enforcement efforts, which have suffered high-profile blows from courts' increasing willingness to protect the First Amendment right of drug and device manufacturers to make truthful, non-misleading statements about potential off-label uses of their products. The next major bellwether in off-label prosecutions is likely to be United States v. Facteau, No. 1:15-cr-10076-ADB (D. Mass. filed Apr. 8, 2015), a case in federal court in Boston in which two former executives of a device company are charged with various offenses related to alleged off-label promotion. A number of pretrial motions are pending in Facteau, including motions that raise First Amendment defenses.

If you have questions about these recent developments regarding off-label enforcement, please consult your usual Ropes & Gray advisor.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.